Allurion Technologies Inc. (NYSE:ALUR) Short Interest Update

Allurion Technologies Inc. (NYSE:ALUR) was the target of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 564,900 shares, a decrease of 12.8% from the July 15th total of 648,000 shares. Based on an average trading volume of 1,280,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.4% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Chardan Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Allurion Technologies in a research note on Wednesday, May 15th.

Allurion Technologies Price Performance

Shares of ALUR stock traded down $0.01 during trading on Friday, reaching $0.66. The company had a trading volume of 119,234 shares, compared to its average volume of 939,630. The firm’s 50 day simple moving average is $1.08 and its two-hundred day simple moving average is $1.86. Allurion Technologies has a one year low of $0.64 and a one year high of $6.43. The company has a market capitalization of $31.65 million, a PE ratio of -0.17 and a beta of -0.30.

Hedge Funds Weigh In On Allurion Technologies

An institutional investor recently raised its position in Allurion Technologies stock. Accredited Investors Inc. increased its holdings in shares of Allurion Technologies Inc. (NYSE:ALUR) by 33.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 50,000 shares of the company’s stock after purchasing an additional 12,500 shares during the period. Accredited Investors Inc. owned approximately 0.10% of Allurion Technologies worth $50,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 21.39% of the company’s stock.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.